WASHINGTON — Congressional Democrats forced executives from Amgen, Novartis, and Mallinckrodt to explain their price hikes and compensation packages, during a second day of testimony in a series of hearings about their 18-month investigation into pricing practices.
The House Oversight Committee hearing, which followed a Wednesday grilling of executives from Celgene, Bristol Myers Squibb, and Teva Pharmaceuticals, was nearly as meandering as the first. But it was also punctuated with moments of embarrassment and pointed questions for the executives.
About the Author Reprints
